<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
<Article>
<Journal>
<PublisherName>isfcppharmaspire</PublisherName>
<JournalTitle>Pharmaspire</JournalTitle>
<PISSN>C</PISSN>
<EISSN>o</EISSN>
<Volume-Issue>Volume 11, Issue 1</Volume-Issue>
<PartNumber/>
<IssueTopic>Multidisciplinary</IssueTopic>
<IssueLanguage>English</IssueLanguage>
<Season>January-March, 2019</Season>
<SpecialIssue>N</SpecialIssue>
<SupplementaryIssue>N</SupplementaryIssue>
<IssueOA>Y</IssueOA>
<PubDate>
<Year>2022</Year>
<Month>06</Month>
<Day>14</Day>
</PubDate>
<ArticleType>Pharmaceutics</ArticleType>
<ArticleTitle>Preparation and evaluation of rofecoxib polysaccharide-based matrix tablets using nanoparticular approach</ArticleTitle>
<SubTitle/>
<ArticleLanguage>English</ArticleLanguage>
<ArticleOA>Y</ArticleOA>
<FirstPage>18</FirstPage>
<LastPage>23</LastPage>
<AuthorList>
<Author>
<FirstName>Sankha</FirstName>
<LastName>Bhattacharya</LastName>
<AuthorLanguage>English</AuthorLanguage>
<Affiliation/>
<CorrespondingAuthor>N</CorrespondingAuthor>
<ORCID/>
</Author>
</AuthorList>
<DOI/>
<Abstract>Rofecoxib has a tremendous role in the treatment of colon polyps and Crohn’s disease. However, gastric resistant has always been an issue for drug delivery to the colon. The main intention of this research was to prepare and evaluate an optimized formulation that could resist gastrointestinal fluid and releases drug content not more than 10% within simulated gastric fluid for 2 h from the time of administration. Rofecoxib nanoparticles were prepared using Dyno mill, considering Acconon MC8-2EP as a surfactant and Capmul MCM L-8 as co-surfactant. Freshly prepared rofecoxib nanoparticles were then admixed with Lactopress® anhydrous and using dry granulation technique ten batches of rofecoxib tablets were formulated by altering various ratios of resistant starch, dextran, and gellan gum. Tablets were prepared using a dry granulation technique, where ALTRIN® was considered as a principal binder. All the pre- and post-compression parameters were evaluated and it was found that D-3 batch has a legitimate cumulative percentage dissolution profile, i.e., 98.12% at 24th h. Furthermore, similarity and dissimilarity studies were performed against Orthobid tablets (marketed) and with optimized formulation (D-3). The similarity factor (F2) and difference or dissimilarity factors (F1) were found to be 60.90 and 10.16, respectively, which is within the specified limits. Finally, as per ICH (Q1A (R2) guideline, accelerated stability studies were performed in the D-3 formulation for 6 months. Stability results were reliable and trustworthy for considering as a stable formulation. Hence, it can be concluded that the optimized D-3 batch can be conceded for the pilot scalp.</Abstract>
<AbstractLanguage>English</AbstractLanguage>
<Keywords>Rofecoxib, similarity factor, polysaccharides, Acconon MC8-2EP, accelerated stability studies</Keywords>
<URLs>
<Abstract>https://isfcppharmaspire.com/ubijournal-v1copy/journals/abstract.php?article_id=13872&title=Preparation and evaluation of rofecoxib polysaccharide-based matrix tablets using nanoparticular approach</Abstract>
</URLs>
<References>
<ReferencesarticleTitle>References</ReferencesarticleTitle>
<ReferencesfirstPage>16</ReferencesfirstPage>
<ReferenceslastPage>19</ReferenceslastPage>
<References>1. Langer R. Drug delivery and targeting. Nature 1998;392:5-10.
2. Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: Design trends and approaches. AAPS PharmSciTech 2015;16:731-41.
3. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol toxicol Methods 2000;44:235-49.
4. Amidon GL, Lennernand;auml;s H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20.
5. Bhattacharya S. Preparation and evaluation of celecoxib polysaccharide based matrix tablets using nanoparticular approach. Asian J Pharm 2017;11:S374-81.
6. Shegokar R, Mand;uuml;ller RH. Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm 2010;399:129-39.
7. Sandri G, Bonferoni MC, Rossi S, Caramella CM, Ferrari F. Effects of particle size, surface nature and crystal type on dissolution rate. In: Particles and Nanoparticles in Pharmaceutical Products. Berlin: Springer; 2018. p. 303-28.
8. Bosch HW, Ryde NP. Nanoparticulate Compositions Comprising Copolymers of Vinyl Pyrrolidone and Vinyl Acetate as Surface Stabilizers. United States: Google Patents; 2005.
9. Henry LG, Condon RE, Schulte WJ, Aprahamian C, DeCosse JJ. Risk of recurrence of colon polyps. Ann Surg 1975;182:511.
10. Farooq U, Malviya R, Sharma PK. Design and development of multi particulate system for targeted drug delivery using natural polymer. Pharm Anal Acta 2015;6:366.
11. Zhang L, Jiang Y, Ding Y, Povey M, York D. Investigation into the antibacterial behaviour of suspensions of ZnO nanoparticles (ZnO nanofluids). J Nanopart Res 2007;9:479-89.
12. Arpagaus C. PLA/PLGA nanoparticles prepared by nano spray drying. J Pharm Invest 2019;49:405-26.
13. Troutman M, Bienkowski I, Harris N, Truncellito-Simoni J. Printing Ink and Coating Compositions Containing Derivatives of Starch and Modified Starch. United States: Google Patents; 2010.
14. Breier AR, Paim CS, Steppe M, Schapoval EE. Development and validation of dissolution tests for fexofenadine hydrochloride capsules and coated tablets. J Pharm Pharm Sci 2005;8:289-98.</References>
</References>
</Journal>
</Article>
</ArticleSet>